Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb.
The firm's treatments are based on stimulating the innate immune system with drugs made from inactivated bacteria to restore normal immune function.
The company's "chip-in-a-tube" digital PCR system combines the advantages of droplet- and chip-based systems into a single platform.
The method uses chitosan-coated magnetic beads and bead-based lysis to reduce the number of sample prep steps.
Crowdfunding will help move the targeted sequencing-based test through the development process in hopes of commercializing it.
The firm has launched a line of 60 rapid immunoassays aimed at emerging markets, and plans to emphasize its menu to drive uptake of its molecular platform.
The firm's target market for the instruments will include existing customers in the forensics and food testing spaces.
Recently validated on pseudomonas and TB samples, the business card-sized device also enables on-chip extraction.
The study compared five methods, including three based on Roche test kits and reagents, and suggested that a multiplexed test may be best to avoid false-negative results.
The firm will apply its qPCR-enabling technology to detection kits for highly polymorphic regions of HIV that confer resistance to protease inhibitors.
Funded by a $600 million gift, the Biohub will support investigators at three universities as well as two initial internal projects.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.